Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DUPILUMAB Cause Malignant neoplasm progression? 10 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Malignant neoplasm progression have been filed in association with DUPILUMAB (Dupixent). This represents 0.0% of all adverse event reports for DUPILUMAB.

10
Reports of Malignant neoplasm progression with DUPILUMAB
0.0%
of all DUPILUMAB reports
3
Deaths
4
Hospitalizations

How Dangerous Is Malignant neoplasm progression From DUPILUMAB?

Of the 10 reports, 3 (30.0%) resulted in death, 4 (40.0%) required hospitalization, and 1 (10.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DUPILUMAB. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does DUPILUMAB Cause?

Pruritus (44,279) Dermatitis atopic (33,670) Product use in unapproved indication (33,452) Rash (30,895) Injection site pain (27,799) Drug ineffective (23,712) Dry skin (20,239) Eczema (20,020) Product dose omission issue (18,189) Condition aggravated (16,459)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which DUPILUMAB Alternatives Have Lower Malignant neoplasm progression Risk?

DUPILUMAB vs DURAGESIC DUPILUMAB vs DUROGESIC DUPILUMAB vs DUROTEP MT DUPILUMAB vs DURVALUMAB DUPILUMAB vs DUTASTERIDE

Related Pages

DUPILUMAB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression DUPILUMAB Demographics